Patent profile for the approved and in clinical trials Mpox vaccines.

Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.

Nanoparticles applied to antineoplastic agents: a patent landscape.

Recently, research in the field of cancer nanotechnology has made notable progress, and, with the fast development of nanomaterials, new treatment strategies using nanoparticles are being explored that have the potential to overcome existing problems. The present review focuses on patenting as a key indicator of trends in nanoparticles with applications in the treatment of cancer. The impact of cancer on health and the use of nanoparticles are briefly described. Next, a survey of patents filed in the last 14 years is presented, the patents granted in the last four years are identified, and the focus areas of the main applicants are analyzed. The mix of targets identified for patented nanoparticles systems suggests that polymers and proteins are the main focus of the innovative efforts in this field.

Pipeline of Known Chemical Classes of Antibiotics.

Many approaches are used to discover new antibiotic compounds, one of the most widespread being the chemical modification of known antibiotics. This type of discovery has been so important in the development of new antibiotics that most antibiotics used today belong to the same chemical classes as antibiotics discovered in the 1950s and 1960s. Even though the discovery of new classes of antibiotics is urgently needed, the chemical modification of antibiotics in known classes is still widely used to discover new antibiotics, resulting in a great number of compounds in the discovery and clinical pipeline that belong to existing classes. In this scenario, the present article presents an overview of the R&D pipeline of new antibiotics in known classes of antibiotics, from discovery to clinical trial, in order to map out the technological trends in this type of antibiotic R&D, aiming to identify the chemical classes attracting most interest, their spectrum of activity, and the new subclasses under development. The result of the study shows that the new antibiotics in the pipeline belong to the following chemical classes: quinolones, aminoglycosides, macrolides, oxazolidinones, tetracyclines, pleuromutilins, beta-lactams, lipoglycopeptides, polymyxins and cyclic lipopeptides.